PE20001424A1 - Composiciones que tienen estabilidad mejorada - Google Patents

Composiciones que tienen estabilidad mejorada

Info

Publication number
PE20001424A1
PE20001424A1 PE2000000019A PE0000192000A PE20001424A1 PE 20001424 A1 PE20001424 A1 PE 20001424A1 PE 2000000019 A PE2000000019 A PE 2000000019A PE 0000192000 A PE0000192000 A PE 0000192000A PE 20001424 A1 PE20001424 A1 PE 20001424A1
Authority
PE
Peru
Prior art keywords
solvent
antihistamines
hydroquinone
sodium
ionized
Prior art date
Application number
PE2000000019A
Other languages
English (en)
Inventor
Francis Joseph David Bealin-Kelly
Douglas Joseph Dobrozsi
Richard Matthew Charles Sutton
Brian James Robbins
Jayant Eknath Khanolkar
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE20001424A1 publication Critical patent/PE20001424A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION LIQUIDA ORAL CON ESTABILIDAD MEJORADA UTILIZANDO UN VOLUMEN NO SUPERIOR A 3 ml; QUE COMPRENDE: a)UN PRINCIPIO ACTIVO EN SU FORMA NO IONIZADA QUE TIENE UN PORCENTAJE DE VALOR DE SOLUBILIDAD EN EL DISOLVENTE A TEMPERATURA AMBIENTE SUPEIOR A 0,075%; CON PESO MOLECULAR INFERIOR A 500 gr/mol CAPAZ DE SER IONIZADO EN UN DISOLVENTE ACUOSO Y TIENE UN COEFICIENTE DE PARTICION OCTANOL-AGUA POR LO MENOS DE 100 CUANDO ESTA EN LA FORMA NO IONIZADA TAL COMO ANTITUSIVOS, ANTIHISTAMINAS, ANTIHISTAMINAS NO SEDANTES, DESCONGESTIONANTES, EXPECTORANTES, MUCOLITICOS ANALGESICOS, AGENTES ANTIINFLAMATORIOS, ANTIPIRETICOS, ANESTESICOS LOCALES; b) DE 60% A 99,975% EN PESO DE UN DISOLVENTE ANHIDRO, HIDROFILO, MISCIBLE COMO PROPILENGLICOL, ETANOL, POLI(ETILENGLICOL), CARBONATO DE PROPILENO, MONOETILETER DEL DIETILENGLICOL, POLOXAMER, GLICOFUROL, GLICEROL; c)DE 0,005% A 1,000% DE UN AGENTE DE REDUCCION CON UN VALOR DE POTENCIAL ESTANDAR E° SUPERIOR A -0,119V TAL COMO SALES DE METABISULFITO O BISULFITO DE SODIO O DE POTASIO, DITIOTREITOL, TIOUREA, TIOSULFATO SODICO, ACIDO TIOGLICOLICO, TERC-BUTIL-HIDROQUINONA, ACETIL-CISTEINA, HIDROQUINONA, PARA MEJORAR LA ESTABILIDAD DEL PRINCIPIO ACTIVO
PE2000000019A 1999-01-11 2000-01-10 Composiciones que tienen estabilidad mejorada PE20001424A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11537899P 1999-01-11 1999-01-11
US15654099P 1999-09-29 1999-09-29

Publications (1)

Publication Number Publication Date
PE20001424A1 true PE20001424A1 (es) 2001-01-05

Family

ID=26813133

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000019A PE20001424A1 (es) 1999-01-11 2000-01-10 Composiciones que tienen estabilidad mejorada

Country Status (15)

Country Link
US (1) US20020082307A1 (es)
EP (1) EP1146876A2 (es)
JP (1) JP2002534464A (es)
KR (1) KR20010101476A (es)
CN (1) CN1336822A (es)
AU (1) AU771478B2 (es)
BR (1) BR0007473A (es)
CA (1) CA2356944A1 (es)
CO (1) CO5150215A1 (es)
CZ (1) CZ20012492A3 (es)
HU (1) HUP0105028A3 (es)
NO (1) NO20013441D0 (es)
PE (1) PE20001424A1 (es)
TR (1) TR200101928T2 (es)
WO (1) WO2000041694A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2475376C (en) 2002-02-08 2008-07-22 The Procter & Gamble Company Child resistant sachet
PL2486942T3 (pl) 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20080003280A1 (en) * 2006-06-26 2008-01-03 Levine Brian M Combination cough treatment compounds and method of treating common coughs
CN101842079B (zh) * 2007-08-31 2012-09-05 阿基米德开发有限公司 非水性药物组合物
US7914828B2 (en) * 2008-10-17 2011-03-29 Levine Brian M Combination herbal product to benefit respiratory tract
US8361519B2 (en) 2010-11-18 2013-01-29 Aadvantics Pharmaceuticals, Inc. Combination herbal product to benefit respiratory tract in people exposed to smoke
CN104027326B (zh) * 2013-03-04 2017-09-01 天津康鸿医药科技发展有限公司 盐酸氨溴索雾化吸入剂及其制备方法和应用
WO2018183203A1 (en) * 2017-03-27 2018-10-04 DXM Pharmaceutical, Inc. Packaged multi-dose liquid drug formulation
US11234897B2 (en) 2017-03-27 2022-02-01 DXM Pharmaceutical, Inc. Packaged multi-dose liquid dextromethorphan hydrobromide formulation
CN112312892A (zh) 2018-06-29 2021-02-02 强生消费者公司 用于递送活性物质的三维微流体装置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100898A (en) * 1990-01-25 1992-03-31 Richardson-Vicks Inc. Antitussive liquid compositions containing dyclonine
PL315635A1 (en) * 1994-01-24 1996-11-25 Procter & Gamble Method of solubilising hardly pharmaceutically active substances
US5510389A (en) * 1994-03-02 1996-04-23 The Procter & Gamble Company Concentrated acetaminophen solution compositions
US5616621A (en) * 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
AU7916798A (en) * 1997-05-22 1998-12-11 Boots Company Plc, The Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat

Also Published As

Publication number Publication date
TR200101928T2 (tr) 2001-11-21
HUP0105028A3 (en) 2003-05-28
KR20010101476A (ko) 2001-11-14
BR0007473A (pt) 2001-10-16
CA2356944A1 (en) 2000-07-20
NO20013441L (no) 2001-07-11
WO2000041694A3 (en) 2000-11-30
JP2002534464A (ja) 2002-10-15
AU2847500A (en) 2000-08-01
AU771478B2 (en) 2004-03-25
HUP0105028A2 (hu) 2002-05-29
WO2000041694A2 (en) 2000-07-20
EP1146876A2 (en) 2001-10-24
NO20013441D0 (no) 2001-07-11
CZ20012492A3 (cs) 2001-11-14
US20020082307A1 (en) 2002-06-27
CN1336822A (zh) 2002-02-20
CO5150215A1 (es) 2002-04-29

Similar Documents

Publication Publication Date Title
PE20010627A1 (es) Composiciones que tienen estabilidad mejorada
PE20001415A1 (es) Composiciones que tienen suministro mejorado de activos
PE20001424A1 (es) Composiciones que tienen estabilidad mejorada
PE20080741A1 (es) Formulaciones parenterales de metilnaltrexona y sus sales
PE20071310A1 (es) Formulaciones liquidas de fenilefrina
AR036745A1 (es) Producto en forma de gel liquido de alta eficacia
BRPI0406905A (pt) Espuma de fosfato de clindamicina
AR023114A1 (es) Composiciones antimicrobianas y antivirales que contienen una especie oxidante
PE20001397A1 (es) Composiciones que tienen estabilidad mejorada
CY1114631T1 (el) Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
PE20050175A1 (es) Peliculas consumibles oralmente de disolucion rapida que contienen un almidon modificado para la mejora de la resistencia al calor y a la humedad
PT1819362E (pt) Formulações tópicas de nepafenac
CA2424346A1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
AR040467A1 (es) Una composicion cosmetica solida blanda, libre de agentes tensioactivos y estable
PE20120023A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
AR031450A1 (es) Composiciones orales que tienen caracteristicas esteticas del consumidor mejoradas
AR066905A1 (es) Administracion intranasal de asenapina y composiciones farmaceuticas correspondientes
AR117718A2 (es) Mejoramientos en composiciones farmacéuticas, y relacionados con ellas
CO5640067A2 (es) Una composicion antitranspirante en gel transparente de baja viscosidad de emulsion de agua en aceite
AR029456A1 (es) Forma triturada
RS88404A (en) Low dose liquid entecavir formulation and use
BRPI0606119B8 (pt) preparações injetáveis de diclofenaco e seus sais farmaceuticamente aceitáveis
PE20030545A1 (es) Formulaciones de jarabe de ribavirina
BR0009214A (pt) Composições aquosas estáveis contendo umcomposto de silìcio
ES2179526T3 (es) Analogos y profarmacos del paclitaxel solubles en agua.

Legal Events

Date Code Title Description
FC Refusal